Answers are grounded in this paper and cite their sources.
Background/Objectives: Hepatic arterial infusion chemotherapy (HAIC) is increasingly combined with tyrosine kinase inhibitors, immune checkpoint inhibitors or transarterial chemoembolisation, yet radiomics models seldom distinguish HAIC alone from HAIC within a multi-agent regimen. We reviewed handcrafted or semi-automated radiomics models in HAIC, stratified by regimen. Methods: Following PRISMA 2020 (PROSPERO CRD420261487449), MEDLINE, Embase and Web of Science were searched to 6 November 2026 for English-language studies combining radiomic feature extraction with a machine-learning classifier to predict response, survival or treatment selection; end-to-end deep-learning studies were excluded. Studies were classified as monotherapy, combination regimen or mixed, appraised with the Radiomics Quality Score, PROBAST+AI and METRICS, and synthesised narratively. Results: Eleven studies (2032 patients) were included: five monotherapy, four combination-regimen and two mixed or non-separable-regimen studies. Validation, test or bootstrap AUCs were 0.75–0.90 for monotherapy and 0.86–0.97 for combination-regimen studies; the highest values (0.99) were training-set estimates. Excluding three studies with uncertain regimen widened the gap. Only two had external validation, none shared data or code, and most had high or unclear risk of bias. Conclusions: Handcrafted radiomics models show high but methodologically immature discrimination. Higher combination-regimen AUCs are confounded by tumour type, cohort and pipeline and do not demonstrate a HAIC-specific effect. Funding: none.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: